139 related articles for article (PubMed ID: 21468931)
1. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
Gai WW; Zhang Y; Zhou DH; Chen YQ; Yang JY; Yan HM
Virol Sin; 2011 Apr; 26(2):81-94. PubMed ID: 21468931
[TBL] [Abstract][Full Text] [Related]
2. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.
Iwata-Yoshikawa N; Uda A; Suzuki T; Tsunetsugu-Yokota Y; Sato Y; Morikawa S; Tashiro M; Sata T; Hasegawa H; Nagata N
J Virol; 2014 Aug; 88(15):8597-614. PubMed ID: 24850731
[TBL] [Abstract][Full Text] [Related]
3. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
Sekimukai H; Iwata-Yoshikawa N; Fukushi S; Tani H; Kataoka M; Suzuki T; Hasegawa H; Niikura K; Arai K; Nagata N
Microbiol Immunol; 2020 Jan; 64(1):33-51. PubMed ID: 31692019
[TBL] [Abstract][Full Text] [Related]
4. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
Tseng CT; Sbrana E; Iwata-Yoshikawa N; Newman PC; Garron T; Atmar RL; Peters CJ; Couch RB
PLoS One; 2012; 7(4):e35421. PubMed ID: 22536382
[TBL] [Abstract][Full Text] [Related]
5. Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.
Zhang CH; Lu JH; Wang YF; Zheng HY; Xiong S; Zhang MY; Liu XJ; Li JX; Wan ZY; Yan XG; Qi SY; Cui Z; Zhang B
Vaccine; 2005 May; 23(24):3196-201. PubMed ID: 15837220
[TBL] [Abstract][Full Text] [Related]
6. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen.
Lan J; Deng Y; Chen H; Lu G; Wang W; Guo X; Lu Z; Gao GF; Tan W
PLoS One; 2014; 9(11):e112602. PubMed ID: 25405618
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.
Dillard JA; Taft-Benz SA; Knight AC; Anderson EJ; Pressey KD; Parotti B; Martinez SA; Diaz JL; Sarkar S; Madden EA; De la Cruz G; Adams LE; Dinnon KH; Leist SR; Martinez DR; Schäfer A; Powers JM; Yount BL; Castillo IN; Morales NL; Burdick J; Evangelista MKD; Ralph LM; Pankow NC; Linnertz CL; Lakshmanane P; Montgomery SA; Ferris MT; Baric RS; Baxter VK; Heise MT
Nat Commun; 2024 May; 15(1):3738. PubMed ID: 38702297
[TBL] [Abstract][Full Text] [Related]
8. Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus.
Qiu X; Hong C; Li Y; Bao W; Gao XM
Microbiol Immunol; 2012 Aug; 56(8):554-61. PubMed ID: 22530918
[TBL] [Abstract][Full Text] [Related]
9. MAIT cells activate dendritic cells to promote T
Pankhurst TE; Buick KH; Lange JL; Marshall AJ; Button KR; Palmer OR; Farrand KJ; Montgomerie I; Bird TW; Mason NC; Kuang J; Compton BJ; Comoletti D; Salio M; Cerundolo V; Quiñones-Mateu ME; Painter GF; Hermans IF; Connor LM
Cell Rep; 2023 Apr; 42(4):112310. PubMed ID: 36989114
[TBL] [Abstract][Full Text] [Related]
10. Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model.
Cameron MJ; Kelvin AA; Leon AJ; Cameron CM; Ran L; Xu L; Chu YK; Danesh A; Fang Y; Li Q; Anderson A; Couch RC; Paquette SG; Fomukong NG; Kistner O; Lauchart M; Rowe T; Harrod KS; Jonsson CB; Kelvin DJ
PLoS One; 2012; 7(9):e45842. PubMed ID: 23029269
[TBL] [Abstract][Full Text] [Related]
11. Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Formulation: Preliminary Results on Cytokines and IgG Responses.
Kalanaky S; Fakharzadeh S; Karimi P; Hafizi M; Jamaati H; Hassanzadeh SM; Khorasani A; Mahdavi M; Nazaran MH
Viral Immunol; 2023; 36(6):409-423. PubMed ID: 37506342
[TBL] [Abstract][Full Text] [Related]
12. N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infection.
Hoover AR; More S; Liu K; West CL; Valerio TI; Furrer CL; Adams JP; Yu N; Villalva C; Kumar A; Alleruzzo L; Lam SSK; Hode T; Papin JF; Chen WR
Acta Biomater; 2024 Feb; 175():279-292. PubMed ID: 38160856
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein.
Raghuwanshi D; Mishra V; Das D; Kaur K; Suresh MR
Mol Pharm; 2012 Apr; 9(4):946-56. PubMed ID: 22356166
[TBL] [Abstract][Full Text] [Related]
14. Intranasal COVID-19 vaccines: From bench to bed.
Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X
EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851
[TBL] [Abstract][Full Text] [Related]
15. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.
Enjuanes L; Dediego ML; Alvarez E; Deming D; Sheahan T; Baric R
Virus Res; 2008 Apr; 133(1):45-62. PubMed ID: 17416434
[TBL] [Abstract][Full Text] [Related]
16. Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV.
Wang D; Lu J
Physiol Genomics; 2004 Jul; 18(2):245-8. PubMed ID: 15161967
[TBL] [Abstract][Full Text] [Related]
17. Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge.
King RG; Silva-Sanchez A; Peel JN; Botta D; Dickson AM; Pinto AK; Meza-Perez S; Allie SR; Schultz MD; Liu M; Bradley JE; Qiu S; Yang G; Zhou F; Zumaquero E; Simpler TS; Mousseau B; Killian JT; Dean B; Shang Q; Tipper JL; Risley CA; Harrod KS; Feng T; Lee Y; Shiberu B; Krishnan V; Peguillet I; Zhang J; Green TJ; Randall TD; Suschak JJ; Georges B; Brien JD; Lund FE; Roberts MS
Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452006
[TBL] [Abstract][Full Text] [Related]
18. Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract.
Kocabiyik O; Amlashi P; Vo AL; Suh H; Rodriguez-Aponte SA; Dalvie NC; Love JC; Andrabi R; Irvine DJ
Sci Adv; 2024 May; 10(22):eadn7786. PubMed ID: 38809992
[TBL] [Abstract][Full Text] [Related]
19. Children's vaccines do not induce cross reactivity against SARS-CoV.
Yu Y; Jin H; Chen Z; Yu QL; Ma YJ; Sun XL; Wang B
J Clin Pathol; 2007 Feb; 60(2):208-11. PubMed ID: 17264247
[TBL] [Abstract][Full Text] [Related]
20. Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
Tsunetsugu-Yokota Y; Ohnishi K; Takemori T
Rev Med Virol; 2006; 16(2):117-31. PubMed ID: 16518829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
